₹11,000 Injection, ₹1,30,000 Bill: Inside the Supreme Court’s War on India’s Hospital Drug Markup
EduLaw EditorialLegal UpdatesA man watching his wife fight cancer did what most desperate patients never get the chance to: he checked the price. The hospital’s bill for a single chemotherapy injection read ₹1,30,000. As a medical distributor himself, he knew exactly what that drug cost on the open market roughly ₹11,000. The gap didn’t just anger him; it reached the Supreme Court of India, where a Bench is now asking the Union Government a question most patients are too frightened, too rushed, or too unequipped to ask out loud: where does the rest of the money go? Title: The ₹11,000 vs ₹1,30,000 Question — Supreme Court Confronts India’s Hospital Drug Pricing Crisis Case Name: Kishan Chand Jain v. Ethics and Medical Registration Board (EMRB) (Erstwhile Medical Council of India) & Ors., with connected petition by Dr. Sanjay Kulshrestha v. Union of India Case Number: Writ Petition (Civil) — Public Interest Litigation (diary/registration number to be confirmed from the Supreme Court’s official cause list) Court: Supreme Court of India Judges: Justice Vikram Nath and Justice Sandeep Mehta Judgment Date: Matter pending; interim hearings held on September 16, September 22, September 29, and October 12, 2026, with the case next listed on October 27, 2026 (final judgment date to be updated on disposal) Citation: To be assigned on final disposal; presently tracked under the Supreme Court’s 2026 PIL diary number (update once officially reported by SCC Online / LiveLaw / Bar & Bench) ABSTRACT This case analysis examines a significant ongoing Public Interest Litigation before the Supreme Court of India concerning the unregulated pricing of life-saving medicines, with particular focus on an incident in which a medical distributor was billed ₹1,30,000 by a hospital for a chemotherapy injection he could independently source for approximately ₹11,000. The matter, heard by a Bench of Justice Vikram Nath and Justice Sandeep Mehta, has already produced strong judicial observations — including references to “broad daylight dacoity” and “carnage” — over the gap between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) of essential drugs. The Court has pressed the Union of India to explain why the Drugs (Prices Control) Order, 2013 regulates only a narrow category of “scheduled” medicines, leaving roughly 80 to 82 percent of the market in non-scheduled formulations where manufacturers enjoy near-total pricing freedom. This piece traces the factual background of the distributor’s chemotherapy injection episode, situates it within the broader PIL on cancer-drug and stent pricing, analyses the statutory framework under the Essential Commodities Act, 1955 and the DPCO, 2013, draws on constitutional jurisprudence on the right to health under Article 21, and evaluates the Centre’s interim response capping trade margins on anti-cancer drugs at 30 percent of MRP. It concludes by assessing what a uniform margin regime could mean for patients, hospitals, and the pharmaceutical distribution chain going forward. TABLE OF CONTENTS Introduction: When a Distributor Becomes a Patient Factual Background of the Case Issues Before the Supreme Court Statutory and Constitutional Framework Arguments of the Parties Judicial Observations and Reasoning The Centre’s Response and Its Limits Critical Analysis and Way Forward INTRODUCTION: WHEN A DISTRIBUTOR BECOMES A PATIENT Most patients who are overcharged for medicine never find out. They do not know what a drug costs the hospital, what the manufacturer charged the stockist, or what margin sits quietly between the two. This case is different precisely because the man at the centre of it does know. As a medical distributor, he moves these drugs for a living; he understands invoices, trade margins, and wholesale rates better than almost anyone outside the pharmaceutical industry. When his own wife needed a chemotherapy injection and the hospital billed him ₹1,30,000 for it, he was not looking at an abstract statistic — he was looking at a drug he could, by his own professional knowledge, obtain for closer to ₹11,000. That first-hand collision between insider knowledge and patient helplessness is what has given this matter before the Supreme Court its unusual emotional and evidentiary force, inside a wider Public Interest Litigation that has already rattled the pharmaceutical and hospital industry over the past several weeks. FACTUAL BACKGROUND OF THE CASE The broader litigation was initiated through petitions filed by advocate Kishan Chand Jain and paediatric surgeon Dr. Sanjay Kulshrestha, seeking judicial intervention against the unregulated pricing of medicines, mandatory generic prescriptions, and price caps on medical devices. During hearings through September and October 2026, the Supreme Court was shown repeated examples of extraordinary price gaps in cancer treatment: a drug supplied to retailers for around ₹2,700 carrying a printed Maximum Retail Price of ₹27,000; another priced at roughly ₹3,520 against the retailer but billed at approximately ₹22,427 to the patient; and an Indian-made cardiac stent supplied at around ₹5,000 but sold at an MRP of ₹25,000. It is within this pattern — and reportedly raised during the proceedings around the chemotherapy-treatment experience described by the distributor-petitioner-in-person — that the ₹11,000-to-₹1,30,000 example entered the Court’s attention. The distributor’s account was not a hypothetical submitted by a lawyer; it was lived experience, offered as direct evidence that the markup problem is not confined to manufacturer-to-retailer pricing but compounds further once a drug crosses a hospital’s own pharmacy counter, where captive purchasing policies often leave a patient with no alternative but to pay whatever is billed. ISSUES BEFORE THE SUPREME COURT The Bench of Justice Vikram Nath and Justice Sandeep Mehta has framed the dispute around several interlinked questions. First, whether the existing statutory mechanism under the Drugs (Prices Control) Order, 2013 is adequate when it fixes ceiling prices for only around 1,000 “scheduled” formulations, while an estimated 80 to 82 percent of medicines by market value remain “non-scheduled” and therefore free of any upfront price control, subject only to a 10 percent annual increase cap once a manufacturer has fixed the initial price. Second, whether hospitals that compel patients to purchase medicines exclusively through an in-house or empanelled pharmacy — denying treatment or creating obstacles if a patient sources drugs externally — are engaging in an unfair and potentially unconscionable trade practice. Third, whether a uniform retail margin, modelled on the 16 percent margin currently applied to scheduled medicines, should be extended across the entire pharmaceutical and medical-device market rather than being left industry-specific or drug-specific. Fourth, and tied directly to the distributor’s own account, whether government-funded and reimbursement-linked treatment — including schemes such as Ayushman Bharat — effectively launders inflated private pricing into public expenditure, since hospitals that purchase at inflated MRPs are later reimbursed from public funds for those same inflated costs. STATUTORY AND CONSTITUTIONAL FRAMEWORK Drug pricing in India is presently governed by the Drugs (Prices Control) Order, 2013, issued under Section 3 of the Essential Commodities Act, 1955, which empowers the Central Government to regulate the production, supply, and distribution of, and trade and commerce in, essential commodities — a category that includes drugs. Under the DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for “scheduled” formulations listed in the National List of Essential Medicines, while non-scheduled drugs are left largely to market forces, with manufacturers free to fix the launch price and thereafter increase it by no more than 10 percent annually. This statutory gap is precisely what the petitioners argue has allowed cancer drugs, cardiac stents, and chemotherapy injections — life-saving products with effectively zero consumer bargaining power — to carry retail markups of 10 times cost or more. Running alongside this statutory architecture is the constitutional guarantee under Article 21, which the Supreme Court has consistently read to include the right to health and access to medical treatment as a facet of the right to life, reinforced by the Directive Principle under Article 47 obliging the State to regard the raising of public health as among its primary duties. ARGUMENTS OF THE PARTIES Petitioner Kishan Chand Jain, appearing in person before the Court, argued that the absence of upfront price control over non-scheduled medicines effectively hands manufacturers unchecked discretion at the moment of launch, with the 10 percent annual cap operating only after an artificially inflated base price has already been fixed — a loophole, he submitted, that defeats the very purpose of the Essential Commodities Act regime. He placed before the Court multiple comparative examples of PTR-to-MRP gaps, including the cancer and cardiac-device figures referenced above, and the Court noted the chemotherapy-injection experience as a vivid, real-world instance of how that gap plays out for an actual patient’s family rather than merely on a pricing chart. Senior counsel Kapil Sibal, assisting the Court, pressed the additional concern of retail and hospital-level pricing, arguing that even if manufacturer-side controls were tightened, a hospital’s captive-pharmacy practice could independently reproduce the same exploitative markup. For the Union of India, Solicitor General Tushar Mehta and Additional Solicitor General Aishwarya Bhati submitted that drug-pricing policy must balance affordability against the availability of medicines and the health of the pharmaceutical market, cautioning against a blanket price-control approach that could discourage investment or innovation, and informed the Court that the Centre had, in the interim, decided to cap trade margins on anti-cancer drugs specifically at 30 percent of MRP. JUDICIAL OBSERVATIONS AND REASONING The Bench’s language through successive hearings has been unusually direct for interim PIL proceedings. At the September 22 hearing, the Court described the ₹2,700-to-₹27,000 markup as “broad daylight dacoity” against patients, with Justice Mehta asking pointedly how a patient could be “cheated” in this manner. By the September 29 hearing, the Court went further, calling the pattern “carnage” and pressing Solicitor General Mehta to explain, “where does this chunk of money go?” — a question that sits at the exact centre of the distributor’s chemotherapy-injection account, since he, unlike most patients, could actually answer it from his own trade knowledge. The Court also flagged, as a matter of serious concern, complaints that corporate hospitals insist patients purchase medicines only from an in-house or designated pharmacy, with treatment allegedly not assured if medicines are sourced elsewhere, observing that “why should the common man suffer all this?” Significantly, the Bench connected the pricing disparity to public finance, noting that when treatment is covered under Ayushman Bharat or similar government schemes, inflated medicine costs are ultimately borne through public money, raising the spectre of systemic overbilling disguised as routine hospital procurement. THE CENTRE’S RESPONSE AND ITS LIMITS At the October 12 hearing, the Union Government informed the Court that it had decided to cap trade margins on anti-cancer medicines at 30 percent of MRP, with a periodically updated list of covered cancer drugs to be notified, excluding only inexpensive formulations. While presented by the Centre as having “addressed” the cancer-drug pricing issue, the Bench was visibly unsatisfied with the scope of the fix, asking why price-control intervention was confined to oncology drugs alone when the same markup pattern was demonstrably present in cardiac stents, commonly used statins, and other routine medicines and medical devices. The Court’s questioning — how would patients actually benefit if manufacturers were still largely left to fix prices, and what justified the differential treatment of cancer drugs versus everything else — signals that the Bench views a cancer-specific 30 percent cap as, at best, a partial and reactive measure rather than the structural reform the petitioners are seeking. The matter stood listed for further hearing on October 27, 2026, by which point the Centre was expected to place a more complete account of its regulatory options before the Court, including whether a uniform 16 percent margin, as already used for scheduled medicines, could realistically be extended across the wider market. CRITICAL ANALYSIS AND WAY FORWARD What makes this litigation consequential beyond its facts is that it forces open a question Indian drug-pricing law has long left conveniently vague: who absorbs the markup once a medicine leaves the factory gate, and why should that markup differ so dramatically depending on whether a drug happens to sit inside or outside the NPPA’s scheduled list. The chemotherapy-injection episode — a distributor paying ₹11,000 on the open market for a drug his own hospital billed him ₹1,30,000 for — is a nearly twelvefold difference, higher even than the ₹2,700-to-₹27,000 example that first drew the Court’s “broad daylight dacoity” remark, and it exposes a second, distinct layer of overcharging that operates at the hospital-pharmacy level, independent of whatever markup already exists between manufacturer and retailer. A reform limited to oncology-specific trade-margin caps, as the Centre has so far proposed, does not reach this hospital-level layer at all, since a captive in-house pharmacy can still mark up an already-capped MRP item through bundling, administration charges, or simply refusing to honour the patient’s right to purchase externally. For meaningful change, legal observers following the case suggest the Court may need to examine three threads together: extending upfront, pre-launch pricing scrutiny to non-scheduled essential and life-saving drugs rather than regulating only the annual increase; imposing enforceable transparency obligations on hospitals regarding in-house pharmacy markups and empanelment practices; and tightening reimbursement audits under public health schemes so that inflated private billing cannot be quietly passed on to the taxpayer. Until the Supreme Court’s final directions in Kishan Chand Jain emerge, the case stands as one of the clearest judicial acknowledgements yet that India’s patients — and not only professional insiders like the distributor at the heart of this story — deserve to know exactly where their money goes.